BMN 673 is a potent inhibitor of the PARP (poly ADP-ribose polymerase) enzyme family, particularly PARP1 and PARP2. It is primarily investigated for its use in cancer therapy, especially in tumors with deficiencies in DNA repair pathways such as those with BRCA1 or BRCA2 mutations. By inhibiting PARP, BMN 673 prevents cancer cells from repairing DNA damage, leading to selective cell death in malignant cells while sparing normal cells. It has shown promising activity in preclinical models of breast, ovarian, and prostate cancers with homologous recombination deficiencies. Due to its high potency and ability to cross the blood-brain barrier, BMN 673 is also being explored for the treatment of central nervous system tumors and metastases. Its mechanism supports use in combination therapies with DNA-damaging agents like chemotherapy or radiation to enhance antitumor effects.